

Research Article

Development of a Marvellous Polyherbal Formulation BASANT that Eliminates HPV-16 Preventing Carcinoma of Cervix and Various Undesirable Vaginal Infections

G.P. Talwar ^{1*}, Rajyashree Sharma ², Aruna Mittal ³, Sajad A. Dar ⁴, Jagdish C. Gupta⁵, Alok C. Bharti⁶

¹ Talwar Research Foundation, New Delhi.

² Jawaharlal Nehru Medical College, Aligarh, Uttar Pradesh.

³ Institute of Pathology, Safdarjung Hospital Campus, New Delhi.

⁴ Talwar Research Foundation, New Delhi.

⁵ Talwar Research Foundation, New Delhi.

⁶ Zoology Department of Zoology, University of Delhi, New Delhi.

***Corresponding Author:** G.P. Talwar, Director Research Talwar research Foundation E-8, Neb Valley, New Delhi-110068, India. Tel: 00962795420286; Fax: 00962795420286; E-mail: gptalwar@gmail.com

Citation: GP Talwar, Rajyashree Sharma, Aruna Mittal, Sajad A Dar, Jagdish C Gupta, et al. (2023) Development of a Marvellous Polyherbal Formulation BASANT that Eliminates HPV-16 Preventing Carcinoma of Cervix and Various Undesirable Vaginal Infections. *Cancer Prog Diagn* 7: 138.

Received: March 24, 2023; **Accepted:** April 15, 2023; **Published:** April 20, 2023.

Copyright: © 2023 GP Talwar, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Carcinoma of cervix is a major killer of women due to Cancers. It is the second largest cancer of women worldwide, with 604,100 new cases and 341,831 deaths in 2020 [1]. In India also, it is the second leading cause of cancer deaths for females [2]. The American Cancer Society's estimates about 13,960 new cases of invasive cervical cancer and about 4310 deaths in the United States in 2023[<https://www.cancer.org/cancer/cervical-cancer/about/key-statistics.html>].

Carcinoma of cervix is caused by a virus, Human Papilloma Virus (HPV). HPV-16 and/or HPV-18 infection of cervical cells renders Pap smear abnormal and leads through various stages to carcinoma of cervix. We have developed a Polyherbal formulation named BASANT (meaning Spring season), which has praise-worthy properties

Citation: GP Talwar, Rajyashree Sharma, Aruna Mittal, Sajad A Dar, Jagdish C Gupta et al. (2023) Development of a Marvellous Polyherbal Formulation BASANT that Eliminates HPV-16 Preventing Carcinoma of Cervix and Various Undesirable Vaginal Infections. *Cancer Prog Diagn* 7: 138.

of not only killing HPV-16/18 but also eliminating this virus entrenched in cervical cells. Reproduced below are the results of a clinical trial concluded in 11 women positive for HPV. They were administered a Capsule of BASANT intra-vaginally every night for 30 days. On re-examination, 11 out of 11 women became HPV negative.

Table 1a: Pre and post treatment with BASANT of HPV-16 positive patients [3].

S.No.	Age	Parity	HPV-16 Pre-treatment	HPV-16 Post-treatment
1.	42	3+0	+VE	NEGATIVE
2.	27	4+0	+VE	NEGATIVE
3.	35	3+0	+VE	NEGATIVE
4.	28	1+1	+VE	NEGATIVE
5.	45	3+0	+VE	NEGATIVE
6.	35	4+0	+VE	NEGATIVE
7.	30	2+1	+VE	NEGATIVE
8.	45	2+0	+VE	NEGATIVE
9.	38	5+2	+VE	NEGATIVE
10.	35	3+1	+VE	NEGATIVE
11.	38	3+1	+VE	NEGATIVE

Polyherbal formulation named as BASANT, is composed of Curcumin (diferuloyl methane), Aloe vera, purified extracts of Amla (*Embllica Officinalis*) and Neem (*Azadirachta Indica*) along with pharmacopially approved excipients [4]. It is dispensed in powder form in Capsules.

BASANT is also effective against a variety of infections such as all WHO strains of *Neisseria gonorrhoeae*, including those resistant to antibiotics such as Penicillin, Tetracycline, Nalidixic acid and Ciprofloxacin (Table 1).

Table 1b: WHO strains of *Neisseria gonorrhoeae* inhibited by BASANT [4].

Standard WHO strains	Antibiotic resistance	Growth at different concentrations (v/v) of Basant after 24 h			
		5%	2%	1%	0%
<i>N. gonorrhoeae</i> WHO-C	None	-	-	+	+
<i>N. gonorrhoeae</i> WHO-G	Tetracycline (TRNG), nalidixic acid	-	-	-	+
<i>N. gonorrhoeae</i> WHO-K	Penicillin (PPNG), nalidixic acid, ciprofloxacin, ceftriaxone less sensitive	-	-	-	+

<i>N. gonorrhoeae</i> WHO-L	Penicillin (PPNG), nalidixic acid, ciprofloxacin, ceftriaxone less sensitive	-	-	-	+
<i>N. gonorrhoeae</i> 1586	Nalidixic acid, ciprofloxacin	-	-	-	+
<i>N. gonorrhoeae</i> 1669	Nalidixic acid, ciprofloxacin	-	-	+	+
<i>N. gonorrhoeae</i> 1794	Nalidixic acid, ciprofloxacin	-	-	+	+
<i>N. gonorrhoeae</i> 2182	Nalidixic acid, ciprofloxacin	-	-	-	+
<i>N. gonorrhoeae</i> 2436	Penicillin (PPNG), tetracycline (TRNG), nalidixic acid, ciprofloxacin	-	-	-	+
<i>N. gonorrhoeae</i> 2482	Penicillin (PPNG), nalidixic acid, ciprofloxacin	-	-	-	+
<i>N. gonorrhoeae</i> 2676	Penicillin (PPNG), tetracycline (TRNG), nalidixic acid, ciprofloxacin less sensitive	-	-	+	+

BASANT has also shown efficacy against *Candida glabrata*, *Candida albicans* and *Candida tropicalis* including strains resistant to azole drugs and amphotericin B (Table 2). BASANT inhibits *Chlamydia trachomatis*, whether present in free-state or within a cell [5].

Table 2: Clinical isolates of *Candida* species inhibited by BASANT [4].

Clinical isolates of <i>Candida</i> Species Antibiotic resistance		Growth at different concentrations (v/v) of Basant after 24 h			
		5%	2%	1%	0%
<i>C. glabrata</i> ATCC 90030	None	0 CFU/mL	0	$0-0.064 \times 10^8$ CFU/mL	$1.38-1.49 \times 10^8$
<i>C. glabrata</i> (7 clinical isolates)	None	0 CFU/mL	0	$0-0.090 \times 10^8$ CFU/mL	$1.30-1.50 \times 10^8$
<i>C. glabrata</i> (2 clinical isolates)	Fluconazole, itraconazole, ketoconazole, voriconazole, amphotericin B	0 CFU/mL	0	$0-0.075 \times 10^8$ CFU/mL	$1.40-1.50 \times 10^8$
<i>C. albicans</i> ATCC 36082	None	0 CFU/mL	0	$0-0.077 \times 10^8$ CFU/mL	$1.40-1.47 \times 10^8$
<i>C. albicans</i> (5 clinical isolates)	None	0 CFU/mL	0	$0.05-0.08 \times 10^8$ CFU/mL	$1.37-1.50 \times 10^8$
<i>C. albicans</i>	Fluconazole, itraconazole, ketoconazole, voriconazole, amphotericin B	0 CFU/mL	0	$0-0.067 \times 10^8$ CFU/mL	$1.33-1.40 \times 10^8$
<i>C. tropicalis</i> (2 clinical isolates)	None	0 CFU/mL	0	$0.04-0.07 \times 10^8$ CFU/mL	$1.35-1.41 \times 10^8$

Citation: GP Talwar, Rajyashree Sharma, Aruna Mittal, Sajad A Dar, Jagdish C Gupta et al. (2023) Development of a Marvellous Polyherbal Formulation BASANT that Eliminates HPV-16 Preventing Carcinoma of Cervix and Various Undesirable Vaginal Infections. *Cancer Prog Diagn* 7: 138.

To sum up, BASANT is a marvelous formulation totally free of side effects and effective against a whole range of vaginal infections, and eliminates HPV16 from the infected cells on path of progression to carcinoma of cervix. BASANT is passed onto M/s Bipha Drugs, Kottayam, Kerala for making it available to women all over the world at a modest cost.

References

1. International Agency for Research on Cancer. (2020) Globocan.
2. India State-Level Disease Burden Initiative Cancer Collaborators. The burden of cancers and their variations across the states of India: The Global Burden of Disease Study 1990–2016. (2018) *Lancet Oncol* 19: 1289–1306.
3. Talwar GP, Sharma R, Singh S, Das BC, Bharti AC et al. (2015) BASANT, a Polyherbal Safe Microbicide Eliminates HPV-16 in Women with Early Cervical Intraepithelial Lesions. *Journal of Cancer Therapy* 6: 1163-1166.
4. Talwar GP, Dar SA, Rai MK, Reddy KV, Mitra D, et al. (2008) A novel Polyherbal microbicide with inhibitory effect on bacterial, fungal and viral genital pathogens. *Int J Antimicrob Agents* 32: 180–185.
5. Bhengraj AR, Dar SA, Talwar GP, Mittal A et al. (2008) Potential of a novel polyherbal formulation BASANT for prevention of Chlamydia trachomatis infection. *Int J Antimicrob Agents* 32: 84–88.